Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer - results of a large case-control study
Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer - results of a large case-control study
复制标题
DOI：
10.1093/carcin/bgm240
复制
发表时间：
2008-01-01
期刊：
影响因子：
4.7
通讯作者：
Chang-Claude, Jenny
中科院分区：
文献类型：
--
作者：
Abbas, Sascha;Linseisen, Jakob;Chang-Claude, Jenny
各种研究表明，维生素D可以降低乳腺癌的风险。大多数研究仅评估了饮食摄入的影响，尽管内源性生产是维生素D的重要来源。因此，血清25-羟基维生素D [25（OH）D]的测量更好地指示整体维生素D状态。为了评估血清25（OH）D浓度与绝经后乳腺癌风险的相关性，我们在德国进行了一项基于人群的病例对照研究，该研究招募了2002年至2005年间年龄在50-74岁之间的乳腺癌患者。通过个人访谈收集有关社会人口学和乳腺癌危险因素的信息。在这项分析中，我们纳入了1394例病例和1365例对照，在出生年份和采血时间上匹配。采用条件Logistic回归计算乳腺癌的优势比（OR），调整潜在的混杂因素。血清25（OH）D浓度与绝经后乳腺癌风险呈显著负相关。与最低类别（< 30 nM）相比，25（OH）D较高类别的OR [95%置信区间（CI）]（30-45、45-60、60-75和>= 75 nM）分别为0.57（0.45-0.73）、0.49（0.38-0.64）、0.43（0.32-0.57）和0.31（0.24-0.42）（P趋势< 0.0001）。使用分数多项式的分析表明非线性关联。与过去和现在使用者相比，从未使用过绝经期激素治疗（HT）的女性中的相关性更强（P-交互作用< 0.0001）。我们的研究结果强烈表明，通过更好的维生素D供应对绝经后乳腺癌具有保护作用，其特征在于血清25（OH）D测量，在血清25（OH）D浓度低（< 50 nM）的女性中具有更强的负相关性。
Various studies suggest that vitamin D may reduce breast cancer risk. Most studies assessed the effects of dietary intake only, although endogenous production is an important source of vitamin D. Therefore, the measurement of serum 25-hydroxyvitamin D [25(OH)D] better indicates overall vitamin D status. To assess the association of 25(OH)D serum concentrations with post-menopausal breast cancer risk, we used a population-based case-control study in Germany, which recruited incident breast cancer patients aged 50-74 between 2002 and 2005. Information on sociodemographic and breast cancer risk factors was collected by personal interview. For this analysis, we included 1394 cases and 1365 controls, matched on year of birth and time of blood collection. Conditional logistic regression was used to calculate odds ratios (ORs) for breast cancer adjusted for potential confounders. Serum 25(OH)D concentration was significantly inversely associated with post-menopausal breast cancer risk. Compared with the lowest category (< 30 nM), OR [95% confidence intervals (CI)] for the higher categories of 25(OH)D (30-45, 45-60, 60-75 and >= 75 nM) were 0.57 (0.45-0.73), 0.49 (0.38-0.64), 0.43 (0.32-0.57) and 0.31 (0.24-0.42), respectively (P-trend < 0.0001). Analysis using fractional polynomials indicated a non-linear association. The association was stronger in women never using menopausal hormone therapy (HT) compared with past and current users (P-interaction < 0.0001). Our findings strongly suggest a protective effect for post-menopausal breast cancer through a better vitamin D supply as characterized by serum 25(OH)D measurement, with a stronger inverse association in women with low serum 25(OH)D concentrations (< 50 nM).